You are here

Cost effectiveness of screening and preemptive therapy for HIV-associated talaromycosis

Cost effectiveness of screening and preemptive therapy for HIV-associated talaromycosis

Project Summary

The objective is to estimate and compare the costs and the health outcomes (mortality) of a novel strategy of screening and providing preemptive antifungal therapy for asymptomatic talaromycosis in people with advanced HIV disease in SE Asia compared to a strategy of no screening and providing treatment of disseminated disease. The project will utilize data from the Cryptococcal Retention in Care (CRIC) cohort and an ongoing prospective talaromycosis screening study conducted in Vietnam.

Timeline and desired outcomes

Week 1-2: Data acquisition, merging, cleaning, literature review Week 3-4: Gather similar cost data from IVAP study and from multiple cryptococcal antigen screening studies in Asia and Africa. Estimate costs of intervention (screening and preemptive treatment) versus standard of care (no screening and treating disseminated disease) Week 5-6: Conduct cost effectiveness analyses Week 7-10: Preparing manuscript for publication

Expectations for intern

Experience in data cleaning and analysis of large data sets is required or desirable. The intern will be working under the supervision of Dr. Thuy Le and a senior health economist (at Duke or outside of Duke) and will acquire skills in cost effectiveness analyses.